The short version of REV-ERB agonist fits in a sentence. The long version — which is the one that helps — is below.
This page was last updated on 2026-01-24 and is reviewed periodically as new material appears.
SR9009 is often grouped with compounds studied for circadian and metabolic regulation rather than with classical anabolic steroids. Its interactions with nuclear receptors differ from those of androgen receptor ligands, and its proposed mechanisms involve transcriptional control rather than direct hormone signaling. Some sources classify it as a metabolic modulator because of observed effects on energy utilization. The distinction matters for regulation and for interpreting research results across different compound classes.
SR9009 is a synthetic small molecule developed as a REV-ERB agonist. It binds to REV-ERBα and REV-ERBβ, nuclear receptors that help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, the compound alters lipid and glucose handling and influences skeletal muscle oxidative capacity. Its exact effects in humans remain largely uncharacterized because controlled clinical trials have not been reported. The molecule is frequently described in preclinical literature as a metabolic modulator.
Research interest in SR9009 grew from studies showing improved running endurance in mice after short treatment periods. Those experiments linked the compound to increased mitochondrial content and fatty acid oxidation in muscle, but the findings come from animal models and specific dosing schedules. Independent replication has been limited, and the pathways connecting REV-ERB activation to exercise performance are still being mapped. Whether similar responses occur in humans is an open question.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C20H24ClN3O4S | Reported for the free base |
| Molecular weight | 437.9 g/mol | Calculated from the formula |
| Primary target | REV-ERBα and REV-ERBβ | Nuclear receptors involved in circadian regulation |
| Solubility | Soluble in DMSO and ethanol | Poorly soluble in water |
| Typical storage | -20 °C, desiccated | Protect from light and moisture |
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
SR9009 is supplied as a solid research chemical, often in milligram quantities. Laboratories typically weigh it in a controlled environment because fine powders can disperse. Stock solutions are commonly prepared in dimethyl sulfoxide and stored in small aliquots to reduce freeze-thaw cycles. Personal protective equipment and chemical fume hoods are standard when handling unknown or potent compounds. These practices address laboratory safety rather than human use.
Identity and purity of SR9009 samples are usually checked with chromatographic and spectrometric methods. High-performance liquid chromatography can separate the compound from related impurities, while mass spectrometry provides molecular mass confirmation. Nuclear magnetic resonance spectroscopy may be used for structural verification in research settings. No single method proves biological activity, and certificates of analysis should be reviewed alongside raw data. Independent testing is often needed because online products vary widely.
Human activities have caused population decreases or extinction in many bird species. Over a hundred bird species have gone extinct in historical times, although the most dramatic human-caused avian extinctions, eradicating an estimated 750–1800 species, occurred during the human colonisation of Melanesian, Polynesian, and Micronesian islands. Many bird populations are declining worldwide, with 1,227 species listed as threatened by BirdLife International and the IUCN in 2009. There have been long-term declines in North American bird populations, with an estimated loss of 2.9 billion breeding adults, about 30% of the total, since 1970. The most commonly cited human threat to birds is habitat loss. Other threats include overhunting, collisions with buildings or vehicles, long-line fishing bycatch, pollution (including oil spills and pesticide use), competition and predation from nonnative invasive species, and climate change. Governments and conservation groups work to protect birds, either by passing laws that preserve and restore bird habitat or by establishing captive populations for reintroductions. Such projects have produced some successes; one study estimated that conservation efforts saved 16 species of bird that would otherwise have gone extinct between 1994 and 2004, including the California condor and Norfolk parakeet. Human activities have allowed the expansion of a few temperate area species, such as the barn swallow and European starling.
=== Protein-based materials and sustainability === A major strand of Mezzenga's work concerns the development of protein-derived and food-based materials as sustainable platforms for advanced technologies. His group has pioneered the use of amyloid fibrils as building blocks for functional nanocomposites, including biodegradable materials with sensing and shape-memory properties. In 2016, Mezzenga and collaborators reported amyloid–carbon hybrid membranes for universal water purification. The technology exploits supramolecular metal–ligand interactions between heavy-metal ions and protein amyloid fibrils, allowing simultaneous removal of a wide range of contaminants with high binding affinities. The membranes exhibit unusually high permeability, enabling operation with minimal energy input. This research led to patented technologies and the creation of an ETH Zurich spin-off company, BluAct Technologies, which has tested and deployed the approach in multiple countries. Mezzenga has also contributed to the development of conceptual frameworks for evaluating the sustainability of water purification technologies at large, emphasizing energy efficiency and material performance.
radioactive decay The process by which an unstable atomic nucleus loses excess nuclear energy by emitting radiation in any of several forms, including as gamma radiation, as alpha or beta particles, or by ejecting electrons from its atomic orbitals.
The U.S. is one of 17 megadiverse countries containing large numbers of endemic species: about 17,000 species of vascular plants occur in the contiguous United States and Alaska, and over 1,800 species of flowering plants are found in Hawaii, few of which occur on the mainland. The United States is home to 428 mammal species, 784 birds, 311 reptiles, 295 amphibians, and around 91,000 insect species. There are 63 national parks, and hundreds of other federally managed monuments, forests, and wilderness areas, administered by the National Park Service and other agencies. About 28% of the country's land is publicly owned and federally managed, primarily in the Western States. Most of this land is protected, though some is leased for commercial use, and less than one percent is used for military purposes. Environmental issues in the United States include debates on non-renewable resources and nuclear energy, air and water pollution, biodiversity, logging and deforestation, and climate change. The U.S. Environmental Protection Agency (EPA) is the federal agency charged with addressing most environmental-related issues. The idea of wilderness has shaped the management of public lands since 1964, with the Wilderness Act. The Endangered Species Act of 1973 provides a way to protect threatened and endangered species and their habitats. The United States Fish and Wildlife Service implements and enforces the Act. In 2024, the U.S. ranked 35th among 180 countries in the Environmental Performance Index.
==== Policy ==== With the increased use of IT systems, privacy violations were increasing rapidly due to the easier access and poor management. As such, the concern of privacy has become an important topic in healthcare. Privacy breaches happen when organizations do not protect the privacy of people's data. There are four types of privacy breaches, which include unintended disclosure by authorized personnel, intended disclosure by authorized personnel, privacy data loss or theft, and virtual hacking. It became more important to protect the privacy and security of patients' data because of the high negative impact on both individuals and organizations. Stolen personal information can be used to open credit cards or other unethical behaviors. Also, individuals have to spend a large amount of money to rectify the issue. The exposure of sensitive health information also can have negative impacts on individuals' relationships, jobs, or other personal areas. For the organization, the privacy breach can cause loss of trust, customers, legal actions, and monetary fines.
Sources: en.wikipedia.org
=== Legal status === Butorphanol is listed under the Single Convention on Narcotic Drugs 1961 and in the United States is a Schedule IV controlled substance with a DEA ACSCN of 9720. The free base conversion ratio of the hydrochloride is 0.69. Butorphanol was originally a Schedule II controlled substance and was later decontrolled at one point.
=== Atherosclerosis === Rapamycin can accelerate degradation of oxidized LDL cholesterol in endothelial cells, thereby lowering the risk of atherosclerosis. Oxidized LDL cholesterol is a major contributor to atherosclerosis.
the alternation of late wood and early wood increments within the annual ring; the influence of wood rays on the radial direction; the features of the cell wall structure such as microfibril angle modifications and pits; the chemical composition of the middle lamella. Wood drying may be described as the art of ensuring that gross dimensional changes through shrinkage are confined to the drying process. Ideally, wood is dried to that equilibrium moisture content as will later (in service) be attained by the wood. Thus, further dimensional change will be kept to a minimum. It is probably impossible to completely eliminate dimensional change in wood, but elimination of change in size may be approximated by chemical modification. For example, wood can be treated with chemicals to replace the hydroxyl groups with other hydrophobic functional groups of modifying agents. Among all the existing processes, wood modification with acetic anhydride has been noted for the high anti-shrink or anti-swell efficiency (ASE) attainable without damage to wood. However, acetylation of wood has been slow to be commercialised due to the cost, corrosion and the entrapment of the acetic acid in wood. There is an extensive volume of literature relating to the chemical modification of wood. Drying timber is one method of adding value to sawn products from the primary wood processing industries.
After his release from jail, Colonel Rhodes immediately joined his brother Cecil and the British South Africa Company in the Second Matabele War taking place just north of the Transvaal in Matabeleland. Cecil Rhodes was forced to resign as Prime Minister of Cape Colony in 1896 due to his apparent involvement in planning and assisting in the raid; he also, along with Alfred Beit, resigned as a director of the British South Africa Company. Jameson's raid had depleted Matabeleland of many of its troops and left the whole territory vulnerable. Seizing on this weakness, and a discontent with the British South Africa Company, the Ndebele revolted during March 1896 in what is now celebrated in Zimbabwe as the First War of Independence, the First Chimurenga, but it is better known to most of the world as the Second Matabele War. The Shona joined them soon thereafter. Hundreds of European settlers were killed within the first few weeks of the revolt and many more would die over the next year and a half. With few troops to support them, the settlers had to quickly build a laager in the centre of Bulawayo on their own. Against over 50,000 Ndebele held up in their stronghold of the Matobo Hills the settlers mounted patrols under such people as Burnham, Baden-Powell, and Selous. It would not be until October 1897 that the Ndebele and Shona would finally lay down their arms.
Sources: en.wikipedia.org
It is a synthetic REV-ERB agonist used mainly in preclinical research. It is not an approved medicine for human use.
It binds to REV-ERBα and REV-ERBβ, nuclear receptors involved in circadian and metabolic gene regulation. This can alter transcription of genes related to lipid and glucose metabolism in experimental models.
No controlled human trials have established that effect. Endurance findings come primarily from rodent studies, and human responses remain unknown.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.